DIABETES DRUG WARNING
ANCHOR LEAD: THE FDA WARNS THAT A NEW DIABETES MEDICATION IS ASSOCIATED WITH HEART ATTACKS, ELIZABETH TRACEY REPORTS
The FDA has issued a warning about the diabetes drug rosaglitazone, marketed under the brand name ‘Avandia,’ because of an increased risk of heart attacks in patients taking the drug. Sherita Golden, a diabetes expert at Johns Hopkins, says the risk probably doesn’t justify taking the drug off the market.
GOLDEN: I’m not sure it’s going to be taken off the market quite yet but I think this study raises concern, because we’ve always known that rosaglitazone can exacerbate congestive heart failure because it causes fluid retention. What’s concerning is that it also seems to at least in this meta analysis be associated with myocardial infarction. I think what’s important is that there need to be follow up post marketing surveillance trials to look at long term outcomes in people who’ve been on these drugs for a longer period of time. :28
Rosaglitazone is a relatively recent addition to the array of medications available to manage diabetes, and was welcomed because it works by a novel mechanism. I’m Elizabeth Tracey reporting.